Reference number : 172-2018-2019-Q1-907704, amendment number : 1, agreement type : C, recipient legal name : Tieos Pharmaceuticals Inc., recipient country : CA, recipient province : NB, recipient city : Moncton|Moncton, recipient postal code : E1A 6N9, program name english : Industrial Research Assistance Program – Contributions to Firms, program name french : Programme d’aide à la recherche industrielle – Contributions aux entreprises, program purpose english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, program purpose french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, agreement title english : Cell Line Testing for Tumor Shrinkage, agreement title french : Testing de ligne cellulaire de tumeur en retrait, agreement number : 907704, agreement value : 50000.0, agreement start date : 2018-06-04, agreement end date : 2018-12-31, description english : Tieös Pharmaceuticals is a pre-clinical stage biotech company with the goal of creating novel small molecule inhibitors which target the unique metabolic characteristics of cancer cells.

With the use of advanced AI-based computational biology and 3D in-silico models, we have developed lead polypharmocological compounds which will each target multiple metabolic pathways simultaneously; creating synergies and reducing toxicity. Through a proprietary weighting of cancer specific metabolic pathways, we have now synthesized our five lead compounds and are conducting proof-of-concept in-vitro testing.

At Tieös, we have designed compounds which target onco-specific enzymes simultaneously – our goal is to starve cancer cells of their energy., description french : Testing de ligne cellulaire de tumeur en retrait, expected results english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, expected results french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, additional information english : This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days. The total amended value is 14,560 dollars., additional information french : Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de  92 jours. La valeur totale des modifications est de   14 560 dollars., owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada